Optimi Health to Supply MDMA for Psychedelic Research at Tel Aviv University
In this collaboration, Optimi will supply IPR-TLV with MDMA, which was made from in-house produced active pharmaceutical ingredient (API), to support the institute's research investigating the effects of MDMA on animal models of alcohol addiction.
- In this collaboration, Optimi will supply IPR-TLV with MDMA, which was made from in-house produced active pharmaceutical ingredient (API), to support the institute's research investigating the effects of MDMA on animal models of alcohol addiction.
- Optimi has received the import permit from IPR-TLV and is in the process of obtaining its export permit from Health Canada.
- Expected to commence in the summer of 2024 and conclude in late 2025, this study aligns with Optimi's commitment to supplying MDMA to international researchers advancing mental health and addictions research.
- Commenting on the collaboration, Optimi CEO Bill Ciprick expressed his enthusiasm, stating, "Our agreement with IPR-TLV signifies an exciting entry into the Israeli psychedelics research market for Optimi.